SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,051,534 | +184.3% | 391,231 | +357.2% | 0.05% | +152.6% |
| Q1 2022 | $2,832,000 | -69.6% | 85,572 | -60.9% | 0.02% | -69.4% |
| Q4 2021 | $9,318,000 | +322.0% | 219,051 | +339.5% | 0.06% | +313.3% |
| Q3 2021 | $2,208,000 | +135.6% | 49,841 | +298.1% | 0.02% | +114.3% |
| Q1 2021 | $937,000 | -95.4% | 12,520 | -94.7% | 0.01% | -96.1% |
| Q4 2020 | $20,325,000 | +28.5% | 234,939 | -9.2% | 0.18% | +8.5% |
| Q3 2020 | $15,819,000 | +48.5% | 258,819 | +1.0% | 0.16% | +42.6% |
| Q2 2020 | $10,656,000 | +697.6% | 256,275 | +450.9% | 0.12% | +576.5% |
| Q1 2020 | $1,336,000 | +239.1% | 46,516 | +752.9% | 0.02% | +325.0% |
| Q4 2019 | $394,000 | +13.9% | 5,454 | +153.7% | 0.00% | -33.3% |
| Q1 2018 | $346,000 | -68.1% | 2,150 | -90.9% | 0.01% | -68.4% |
| Q3 2016 | $1,085,000 | -38.6% | 23,560 | -59.8% | 0.02% | -48.6% |
| Q2 2016 | $1,768,000 | -9.2% | 58,670 | -3.4% | 0.04% | -9.8% |
| Q1 2016 | $1,947,000 | – | 60,720 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |